Value creation for medical devices: lessons to be learnt from the pharmaceutical sector
This article was originally published in Clinica
Executive Summary
Over the past few years the pharmaceutical industry has discovered a new talisman - the economic evaluation of medicines. Dr Neil Johnson looks at the achievements of the last few years and outlines the pitfalls that medical device and diagnostic companies should avoid as they become more and more involved in the field.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.